Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 690
- Registration Number
- NCT05091567
- Locations
- 🇺🇸
Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States
🇺🇸SCRI Florida Cancer Specialists PAN, Tallahassee, Florida, United States
A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT05075824
- Locations
- 🇺🇸
Children's Hospital of Michigan; Pediatrics, Detroit, Michigan, United States
🇺🇸Mississippi Center for Advanced Medicine, Madison, Mississippi, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
- Conditions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 72
- Registration Number
- NCT05059080
- Locations
- 🇦🇷
Instituto Ave Pulmo, Mar Del Plata, Argentina
🇧🇷Chronos Pesquisa Clinica, Taguatinga, DF, Brazil
🇺🇦Kyiv Railway Clinical Hospital No2 of Branch Health Center of the JSC Ukrainian Rail, Kyiv, KIEV Governorate, Ukraine
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT05047250
- Locations
- 🇨🇳
The First Affiliated Hospital Of Jinzhou Medical University, Jinzhou City, China
🇨🇳Linyishi Cancer Hospital, Linyi City, China
🇨🇳Jiangsu Cancer Hospital, Nanjing City, China
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05039619
- Locations
- 🇪🇸
Hospital Ramon y Cajal ; Servicio de Reumatologia, Madrid, Spain
🇺🇸University of California San Francisco, San Francisco, California, United States
🇧🇷Universidade Federal de Sao Paulo - UNIFES, Sao Paulo, SP, Brazil
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT05009069
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, China
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT04998851
- Locations
- 🇺🇸
Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, Owosso, Michigan, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT04998812
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇫🇷Hôpital de la Pitié Salpétrière, Paris, France
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT04980222
- Locations
- 🇪🇸
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT04963296
- Locations
- 🇺🇸
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇺🇸Unity Health - White County Medical Center- Rheumatology, Searcy, Arkansas, United States
🇺🇸Providence Medical Foundation, Fullerton, California, United States